Dr Satu Vainikka, CEO commented:

"I am delighted that we are now launching our Chlamydia self-testing product into the UK and Irish markets. With Chlamydia being diagnosed as the fastest growing sexually transmitted disease at the moment, our self-testing pack, as an affordable, easy -to-use and rapid indicator of the presence or absence of the Chlamydia bacterium has the potential to become a first line test against Chlamydia. With the disease having the potential to affect fertility in both sexes, I particularly urge young people looking to start a family to test themselves early. Early detection will mean early intervention and thinking that there is not a problem is just not thinking."

Broker Hybridan was positive about the launch, stating that ValiRx remains far from fully valued at these levels.

We like the model of product on the market generating revenues in the test kits and the more blue sky upside that its proprietary drug development programmes provide in the technology platform, said Hybridan.

Last month, ValiRx completed the sale of its Belgian diagnostic development business, ValiBIO SA, to Singapore Volition Pte Ltd, having received all the funds it was due.

ValiRx continues to retain its significant shareholding in Volition and in the future upside value and growth of the business and integration between the companies is progressing well

http://www.proactiveinvestors.co.uk/companies/news/25504/valirx-aim-stock-out-of-the-doldrums-25504.html

Gonna buy more....this will do good in a year or two (imho)

important rns today - eu patent won can go into production ref cancer treatment

:-))

ValiRx shares soar as cancer test gets EU patent

8:40 am by Jamie Ashcroft ValiRx says the test enables the detection of cancer cells at the stage where chromosomal changes have just taken place and tumor development is about to start. Shares in life science firm ValiRx (LON:VAL) shot up around 35 per cent in early deals after it was granted a new European patents for a cancer screening product.

The test is for a biomarker, called NAV3, which is part of an already ‘well-developed’ test kit. And with the patent being granted the company is now able to begin producing and marketing the product.

ValiRx says the cancer test enables the detection of cancer cells at a time when tumour development is about to start.

This is one of five patent family assets that were acquired last month.

"The granting of this latest patent by the European Patent Office further underpins our global geographic patent coverage,” said chief executive Dr Satu Vainikka.

“I believe, strongly vindicates our establishment of ValiFinn and our recent acquisition from Pharmatest of our Finnish biomarkers business, in this rapidly growing marketplace.”

ValiRx explained that sample kits have already been produced and trialled. Several scientific publications have endorsed the technology, it said.

Following the Pharmatest deal ValiRx now owns the patents and retains all commercial rights to each of the five patent family assets.

It said that it is currently in talks with potential production and clinical partners about these assets.

I hope you bought recently!

More sells than buys!
Do they have money to pay their staff?

They raised 3 million last year.

i did skinny cheers

ahoj - it appears more sells than buys but i was watching for a lot of the time and a high % of sells were in fact buys - stats totally skewed

markymar - yep 3mil was raised

very good news today

Been worth hanging onto for these past 18months after all! onward and upwards!

still waiting for the "onward and upwards!" to happen. have sold half to go into SCLP..but let's see what happens here also!

you are likely to need a degree of patience here - but rest of this year looks promising depends how high you set the bar though :-)))

Have a peek at the interview with Dr George Morris - Link

Interesting recovery.

Yes..nice surprise..hope it continues!

Encouraging SP performance recently

One to hold for paying children education, IMO.

or grandchildren in my case!

Yes, off course dad.

Val stirring at long last!

DirectorsTalk.com – Investment analyst covering ValiRx Plc advises that the company will outperform the market.

"The one analyst offering a 12 month price target expects ValiRx Plc share price to rise to 2.16 in the next year from the last price of 0.48."

http://markets.ft.com/research/Markets/Tearsheets/Forecasts?s=VAL:LSE